The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
Official Title: A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.
Study ID: NCT05872347
Brief Summary: This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Anhui provincial hospital, Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Affiliated Cancer Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Liuzhou people's Hospital, Liuzhou, Guangxi, China
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Harbin Medical University cancer Hospital, Harbin, Heilongjiang, China
Anyang Cancer Hospital, Anyang, Henan, China
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
Xiangyang Central Hospital, Xiangyang, Hubei, China
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Jilin Cancer Hospital, Changchun, Jilin, China
The first hospital of Jilin University, Changchun, Jilin, China
General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
The second people's hospital of neijiang, Neijiang, Sichuan, China
Cancer Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Zhejiang cancer Hospital, Hangzhou, Zhejiang, China
Peking Union Medical College Hospital, Beijing, , China
The First Affiliated Hospital of Bengbu Medical College, Bengbu, , China
Chongqing University Three Gorges Hospital, Chongqing, , China